Environmental factors promoting bladder cancer

Current Opinion in Urology

Volumn 19, Issue 5, 2009, Pages 494-499

  Hirao, Yoshihiko ^a   Kim, Wun Jae ^b   Fujimoto, Kiyohide ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Chungbuk National University   (South Korea)

Author keywords

Bladder cancer; Cigarette smoke; Environmental risk factor; Genetic polymorphism

Indexed keywords

8 OXOGUANINE DNA GLYCOSYLASE 1; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; DYE; GLUTATHIONE TRANSFERASE; PROTEIN; UNCLASSIFIED DRUG;

ANALGESIC AGENT ABUSE; ASTHMA; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER PATIENT; CHRONIC INFLAMMATION; CIGARETTE SMOKING; DETOXIFICATION; DISEASE ASSOCIATION; DNA REPAIR; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIFE EXPECTANCY; MOLECULAR BIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION; REVIEW; RISK FACTOR; SCHISTOSOMIASIS; TUBERCULOSIS;

ARYLAMINE N-ACETYLTRANSFERASE; ASTHMA; DNA GLYCOSYLASES; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; RISK FACTORS; SMOKING; TUBERCULOSIS; URINARY BLADDER NEOPLASMS;

EID: 68949178687     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832eb4ef     Document Type: Review

References (51)

1. Naito S, Tanaka K, Koga H, et al. Cancer occurrence among dyestuff workers exposed to aromatic amines: a long term follow-up study. Cancer 1995; 76:1445-1452.
2. Yasunaga Y, Nakanishi H, Naka N, et al. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. Lab Invest 1997; 77:677-684.
3. Kogevinas M, 't Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14:907-914.
4. Hartge P, Silverman D, Hoover R, et al. Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 1987; 78: 1119-1125. (Pubitemid 17113643)
5. Kantor AF, Hartge P, Hoover RN, et al. Urinary tract infection and risk of bladder cancer. Am J Eidemiol 1984; 119:510-515.
6. El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder cancer. Cancer 1981; 48: 26423-26428.
7. Chen CH, Chiou HY, Hsueh YM, etal. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J Urol 2009; 181:547-552.
8. Nakamura Y, Narukawa T, Yoshinaga J. Cancer risk to Japanese population from the consumption of inorganic arsenic in cooked hijiki. J Agric Food Chem 2008; 56:2536-2540.
9. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151:693-702.
10. Naito S, Koga H, Yamaguchi A, et al. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol 2008; 179:485-490.
11. Shibata A, Paganini-Hill A, Ross RK, et al. Intake of vegetable, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among elderly: a prospective study. Br J Cancer 1992; 66:673-679.
12. Castelao JE, Yuan JM, Gango-Dominguez M, et al. Carotenoids/vitamin Cand smoking-related bladder cancer. Int J Cancer 2004; 110:41 7-423.
13. Jacobs EJ, Henion AK, Briggs PJ, et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 2002; 156:1002-1010.
14. Zeegers MP, Goldbohm RA, van den Brandt PA. Are retinol, Vitamin C, Vitamin E, folate and carotenoids intake associated with bladder cancer risk? Results from the Netherlands cohort study. Br J Cancer 2001; 85: 977-983.
15. Michaud DS, Spiegelman D, Clinton SK, et al. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 2000; 152:1145-1153.
16. Leppert JT, Shvarts O, Kawaoka K, et al. Prevention of bladder cancer: a review. Eur Urol 2006; 49:226-234.
17. Wallace K, Kelsey KT, Schned A, etal. Selenium and risk of bladder cancer: a population-based case-control study. Cancer Prev Res (Phila Pa) 2009; 2:70-73.
18. Hinotsu S, Akaza H, Miki T, etal. Japanese Urological Association. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol 2009; 16:64-69.
19. Thompson IM, Peek M, Rodriguez FR. The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 1987; 137:401-403.
20. Foster F. New Zealand Cancer Registry report. Natl Cancer Inst Monogr 1979; 53:77-80.
21. Marcus PM, Hayes RB, Vineis P, etal. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9:461-467.
22. Garc?́a-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366:649-659.
23. Castelli EC, Mendes-Junior CT, Viana de Camargo JL, Donadi EA. HLA-G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population. Tissue Antigens 2008; 72:149-157.
24. Choudhury A, Elliott F, Iles MM, et al. Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet 2008; 9:69.
25. Green J, Banks E, Berrington A, et al. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000; 83:412-417.
26. Vineis P, Marinelli D, Autrup H, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001; 10:1249-1252.
27. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346-355.
28. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
29. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983; 33:355-359.
30. Sinués B, Pérez J, Bernal ML, et al. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res 1992; 52:4885-4889.
31. Kim WJ, Lee HL, Lee SC, et al. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 2000; 164:209-213.
32. Yu MC, Skipper PL, Taghizadeh K, et al. Acetylator phenotype, aminobiphe-nyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994; 86: 712-716.
33. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 2000; 112-113:357-363.
34. Seidega°rd J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 1986; 7:751-753.
35. Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85:1159-1164.
36. Katoh T, Inatomi H, Kim H, etal. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 1998; 132: 147-152.
37. Ryk C, Berggren P, Kumar R, etal. SM. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005; 113:761-768.
38. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
39. Kim WJ, Kim H, Kim CH, et al. GSTT1-null genotype is a protective factor against bladder cancer. Urology 2002; 60:913-918.
40. Kopps S, Angeli-Greaves M, Blaszkewicz M, et al. Glutathione S-transferase P1 ILE105Val polymorphism in occupationally exposed bladder cancer cases. J Toxicol Environ Health A 2008; 71:898-901.
41. Golka K, Schmidt T, Seidel T, et al. The influence of polymorphisms of glutathione S-transferases M1 and M3 on the development of human urothelial cancer. J Toxicol Environ Health A 2008; 71:881-886.
42. Vispe S, Yung TM, Ritchot J, et al. A cellular defense pathway regulating transcription through poly(ADP-ribosyl)ation in response to DNA damage. Proc Natl Acad Sci U S A 2000; 97:9886-9891.
43. Cairns J. Aging and cancer as genetic phenomena. Natl Cancer Inst Monogr 1982; 60:237-239.
44. Knudson AG Jr. The genetic predisposition to cancer. Birth Defects Orig Artic Ser 1989; 25:15-27.
45. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. J Am Med Assoc 1991; 266:681-687.
46. Lee YS, Lee HS, Park MK, et al. Identification of 8-hydroxyguanine glycosylase activity in mammalian tissues using 8-hydroxyguanine specific monoclonal antibody. Biochem Biophys Res Commun 1993; 196:1545-1551.
47. Tchou J, Kasai H, Shibutani S, et al. 8-oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc Natl Acad Sci U S A 1991; 88:4690-4694.
48. Kim EJ, Jeong P, Quan C, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005; 65:70-75.
49. Klungland A, Rosewell I, Hollenbach S, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci U S A 1999; 96:13300-13305.
50. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 1993; 22:976-982.
51. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16:1243-1245.